Ying Huang - 18 Mar 2026 Form 3 Insider Report for Legend Biotech Corp (LEGN)

Role
Chief Executive Officer, Director
Signature
/s/ James Pepin, Attorney-in-Fact
Issuer symbol
LEGN
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 18:50:06 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Huang Ying Chief Executive Officer, Director C/O LEGEND BIOTECH CORP, 2101 COTTONTAIL LANE, SOMERSET /s/ James Pepin, Attorney-in-Fact 18 Mar 2026 0001967360

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LEGN Ordinary Shares 257,374 18 Mar 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LEGN Share Option (right to buy) 18 Mar 2026 Ordinary Shares 81,788 $1.50 Direct F3
holding LEGN Share Option (right to buy) 18 Mar 2026 Ordinary Shares 3,636 $27.50 Direct F3
holding LEGN Share Option (right to buy) 18 Mar 2026 Ordinary Shares 4,248 $23.53 Direct F4
holding LEGN Share Option (right to buy) 18 Mar 2026 Ordinary Shares 35,728 $1.50 Direct F3
holding LEGN Share Option (right to buy) 18 Mar 2026 Ordinary Shares 121,746 $1.50 Direct F3
holding LEGN Share Option (right to buy) 18 Mar 2026 Ordinary Shares 92,134 $14.12 Direct F3
holding LEGN Share Option (right to buy) 18 Mar 2026 Ordinary Shares 185,340 $27.50 Direct F3
holding LEGN Share Option (right to buy) 18 Mar 2026 Ordinary Shares 55,752 $23.53 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
F2 Includes 43,010 restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 28,119 shares underlying the RSU will vest on March 20, 2026 and the remaining 14,891 shares will vest on June 20, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F3 All of the shares subject to the option are immediately exercisable.
F4 All of the shares subject to the option shall vest on April 3, 2026.
F5 40,000 of the shares subject to the option are immediately exercisable and the remainder shall vest on April 3, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney